<DOC>
	<DOCNO>NCT02109744</DOCNO>
	<brief_summary>To evaluate response chemotherapy drug decitabine combine rapamycin treatment relapse refractory acute myeloid leukemia patient age , treatment newly diagnose leukemia old 65 diagnose .</brief_summary>
	<brief_title>Study Decitabine Combination With Sequential Rapamycin Ribavirin High Risk AML Patients</brief_title>
	<detailed_description>To determine efficacy decitabine follow Rapamycin previously untreated elderly patient able receive standard chemotherapy patient relapse refractory AML , measurement Complete Remission ( CR ) , Complete Remission Incomplete Platelet Recovery ( CRp ) , Partial Remission ( PR ) , event free overall survival ( Arm A ) . To determine safety administration decitabine escalate dos Ribavirin elderly leukemia patient patient relapsed/refractory disease M4/M5 subtypes anticipate express high eukaryotic translation initiation factor 4E ( eIF4E ) diagnosis ( Arm B ) . To establish effect sequential treatment expression phosphoinositide 3-kinase/protein kinase B/mammalian target rapamycin ( PI3K/Akt /mTOR ) pathway proteins eukaryotic translation initiation factor 4E ( eIF4E ) activation Western blot phospho-flow methodology . To correlate clinical response baseline expression phospho-p70S6 Kinase/phosphorylated protein kinase B ( pAKT ) vitro inhibitory effect mammalian target rapamycin ( mTOR ) inhibition rapamycin ribavirin level downstream effector . To determine whether leukemia stem cell phenotype inhibit sequential administration decitabine/rapamycin decitabine/ribavirin .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>4.1.1 Age &gt; /= 18 4.1.2 Diagnosis AML accord World Health Organization ( WHO ) criteria except acute promyelocytic leukemia AND 4.1.3 Refractory AML define failure achieve Complete Remission ( CR ) 2 cycle induction chemotherapy persistence &gt; 40 % bone marrow blast one cycle chemotherapy induction OR 4.1.4 Relapsed AML define evidence disease recurrence achieve document first great Complete Remission ( CR ) OR 4.1.5 Relapsed AML stem cell transplantation . 90 day ( since stem cell infusion ) must elapse transplant emergence recurrent AML OR 4.1.6 Newly diagnose AML patient &gt; 65 year old consider fit standard 7+ 3 chemotherapy decline therapy discussion therapeutic option available . 4.1.7 Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 3 4.2.1 Abnormal renal function evidence calculated creatinine clearance â‰¤ 30 ml/min ( CockcroftGault formula ( Appendix 2 ) 4.2.2 Abnormal liver function : Bilirubin &gt; 2.0 mg/dl , transaminase ( ) 2.5x upper limit normal 4.2.3 Active systemic infection respond antibiotic 4.2.4 Known diagnosis human immunodeficiency virus infection ( HIV ) 4.2.5 Patients postallogeneic transplantation active Graft v . Host Disease ( GVHD ) great grade 1 skin time enrollment . They may donor lymphocyte infusion ( DLI ) within 4 week begin study . 4.2.6 Pregnant breastfeed female subject 4.2.7 Known suspected Central Nervous System ( CNS ) leukemia involvement ; past involvement exclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>